Insider Selling: Exelixis, Inc. (NASDAQ:EXEL) EVP Sells 96,986 Shares of Stock

Exelixis, Inc. (NASDAQ:EXEL) EVP Dana Aftab sold 96,986 shares of the stock in a transaction dated Tuesday, November 5th. The stock was sold at an average price of $35.00, for a total value of $3,394,510.00. Following the completion of the sale, the executive vice president now owns 498,945 shares of the company’s stock, valued at $17,463,075. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.

Dana Aftab also recently made the following trade(s):

• On Wednesday, October 30th, Dana Aftab sold 1,162 shares of Exelixis stock. The shares were sold at an average price of $31.40, for a total value of $36,486.80.
• On Monday, August 12th, Dana Aftab sold 20,883 shares of Exelixis stock. The stock was sold at an average price of $27.06, for a total value of $565,093.98.

Exelixis Stock Up 0.8 %

EXEL stock traded up $0.29 during midday trading on Thursday, hitting $35.80. The company’s stock had a trading volume of 1,764,453 shares, compared to its average volume of 2,076,657. The firm has a market capitalization of $10.22 billion, a price-to-earnings ratio of 22.76, a price-to-earnings-growth ratio of 0.87 and a beta of 0.51. Exelixis, Inc. has a 12 month low of $19.20 and a 12 month high of $36.17. The company has a 50 day moving average of $27.67 and a two-hundred day moving average of $24.56.

Exelixis (NASDAQ:EXEL) last posted its quarterly earnings data on Tuesday, October 29th. The biotechnology company reported $0.40 EPS for the quarter, beating analysts’ consensus estimates of $0.36 by $0.04. The business had revenue of $539.50 million during the quarter, compared to analysts’ expectations of $490.31 million. Exelixis had a return on equity of 20.99% and a net margin of 22.43%. The business’s revenue was up 14.3% compared to the same quarter last year. During the same period in the previous year, the business earned $0.10 earnings per share. On average, analysts anticipate that Exelixis, Inc. will post 1.68 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several equities analysts recently issued reports on the stock. BMO Capital Markets lifted their price objective on shares of Exelixis from $29.00 to $36.00 and gave the company an “outperform” rating in a report on Wednesday, October 30th. Piper Sandler lifted their price target on shares of Exelixis from $33.00 to $36.00 and gave the stock an “overweight” rating in a research note on Wednesday, October 30th. StockNews.com upgraded shares of Exelixis from a “buy” rating to a “strong-buy” rating in a report on Saturday, July 13th. JMP Securities reaffirmed a “market outperform” rating and set a $29.00 price objective on shares of Exelixis in a report on Friday, October 11th. Finally, Morgan Stanley increased their target price on shares of Exelixis from $26.00 to $28.00 and gave the stock an “equal weight” rating in a research report on Friday, October 11th. One analyst has rated the stock with a sell rating, five have issued a hold rating, fourteen have assigned a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $31.44.

Institutional Trading of Exelixis

A number of hedge funds and other institutional investors have recently modified their holdings of EXEL. V Square Quantitative Management LLC acquired a new stake in shares of Exelixis in the third quarter valued at about $30,000. Park Place Capital Corp bought a new position in shares of Exelixis in the second quarter valued at approximately $45,000. GAMMA Investing LLC grew its position in shares of Exelixis by 107.9% in the second quarter. GAMMA Investing LLC now owns 2,006 shares of the biotechnology company’s stock valued at $45,000 after purchasing an additional 1,041 shares in the last quarter. EntryPoint Capital LLC lifted its stake in shares of Exelixis by 537.2% in the 1st quarter. EntryPoint Capital LLC now owns 2,071 shares of the biotechnology company’s stock valued at $49,000 after acquiring an additional 1,746 shares during the last quarter. Finally, Capital Performance Advisors LLP purchased a new stake in Exelixis during the 3rd quarter valued at $61,000. 85.27% of the stock is owned by hedge funds and other institutional investors.

About Exelixis

Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.